REYAGEN study. Optimization of unboosted atazanavir dosing, when associated with tenofovir, guided by pharmacogenetics profile of HIV-patients

Trial Profile

REYAGEN study. Optimization of unboosted atazanavir dosing, when associated with tenofovir, guided by pharmacogenetics profile of HIV-patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jul 2015

At a glance

  • Drugs Atazanavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Pharmacogenomic; Pharmacokinetics
  • Acronyms REYAGEN
  • Most Recent Events

    • 06 Mar 2013 Primary endpoint 'Trough-drug-concentration' has been met.
    • 06 Mar 2013 Status changed from recruiting to completed.
    • 06 Mar 2013 Results presented at the 20th Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top